Home MAPK S6 Kinase

S6 Kinase Inhibitors

Cat.No. Product Name Information Product Use Citations Product Validations
E4345 L-Norvaline L-Norvaline is a non-proteinogenic amino acid, an isomer of valine, and an inhibitor of arginase and p70 ribosomal S6 kinase 1 (p70S6K1) kinase. L-norvaline enhances NO production from activated macrophages.
E4690New Gingerenone A Gingerenone A is a a polyphenol present in ginger, an inhibitor of p70 S6 (S6K1) and an activator of Nrf2-Gpx4 signaling pathway to alleviate ferroptosis in secondary liver injury in colitis. It exhibits anti-adipogenic, anti-lipogenic, anti-hyperglycemic, anti-obesity, and anti-inflammatory effects, and holds promise for research into anti-diabetic and anti-obesity drug development.
S1582 H-89 Dihydrochloride H 89 2HCl is a potent PKA inhibitor with Ki of 48 nM in a cell-free assay, 10-fold selective for PKA than PKG,500-fold greater selectivity than PKC, MLCK, calmodulin kinase II and casein kinase I/II. H 89 2HCl induces autophagy.
Nat Commun, 2025, 16(1):7115
Nucleic Acids Res, 2025, 53(17)gkaf882
Cell Rep Med, 2025, 6(8):102254
Verified customer review of H-89 Dihydrochloride
S1014 SKI-606 (Bosutinib) Bosutinib is a novel, dual Src/Abl inhibitor with IC50 of 1.2 nM and 1 nM in cell-free assays, respectively. Bosutinib also effectively decreases the activity of PI3K/AKT/mTOR, MAPK/ERK and JAK/STAT3 signaling pathways by blocking the phosphorylation levels of p-ERK, p-S6, and p-STAT3. Bosutinib promotes autophagy.
J Exp Clin Cancer Res, 2025, 44(1):290
Blood Adv, 2025, bloodadvances.2024015364
Biochem Pharmacol, 2025, 242(Pt 4):117412
Verified customer review of SKI-606 (Bosutinib)
S1558 AT7867 AT7867 is a potent ATP-competitive inhibitor of Akt1/2/3 and p70S6K/PKA with IC50 of 32 nM/17 nM/47 nM and 85 nM/20 nM in cell-free assays, respectively; this compound shows little activity outside the AGC kinase family.
Exp Gerontol, 2023, 173:112091
Cancers (Basel), 2022, 14(21)5215
Oncoimmunology, 2021, 10(1):1943234
Verified customer review of AT7867
S6385 Prexasertib (LY2606368)

Prexasertib (LY2606368, ACR 368) is a selective ATP competitor inhibitor of Chk1 and Chk2 with IC50s of 1 nM and 8 nM in cell-free assays, respectively. It also inhibits RSK1 with an IC50 of 9 nM in cell-free assay.
Cell Rep Med, 2025, S2666-3791(25)00151-X
Mol Oncol, 2025, 19(6):1633-1650
Biomol Ther (Seoul), 2025, 33(3):458-469
S7563 AT13148 AT13148 is an oral, ATP-competitive, multi-AGC kinase inhibitor with IC50 of 38 nM/402 nM/50 nM, 8 nM, 3 nM, and 6 nM/4 nM for Akt1/2/3, p70S6K, PKA, and ROCKI/II, respectively. Phase 1.
Neoplasia, 2023, 10.1016/j.neo.2023.100948
Cancers (Basel), 2022, 14(23)5943
Br J Cancer, 2021, 10.1038/s41416-021-01442-6
Verified customer review of AT13148
S8518 AD80 AD80, a multikinase inhibitor, shows strong activity against human RET (c-RET), BRAF, S6K, and SRC but was much less active than either AD57 or AD58 against mTOR. The IC50 value for RET is 4 nM.
Nat Commun, 2022, 13(1):2500
Mol Cancer Res, 2020, 18(8):1176-1188
Mol Cancer Res, 2020, 1176-1188
S7752 Pluripotin (SC1) Pluripotin (SC1) is a dual inhibitor of extracellular signal-regulated kinase 1 (ERK1, MAPK3) and RasGAP that maintains embryonic stem cell (ESC) self-renewal. It also inhibits RSK1, RSK2, RSK3 and RSK4 with IC50 of 0.5 µM, 2.5 µM, 3.3 µM and 10.0 µM, respectively.
J Clin Biochem Nutr, 2024, 74(2):97-107
Antiviral Res, 2018, 157:57-67
Reprod Domest Anim, 2018, 53(5):1052-1059